Medical Information Only. Consult your healthcare provider before considering clinical trial enrollment.
Ocular Hypertension
Open-data reference.
57 US clinical trials · 12 currently recruiting
Active & Recent Trials
Implementing AI-based Glaucoma Screening Within Federally Qualified Health Centers
University of Alabama at Birmingham
NCT06629649
Evaluation of the Safety and Efficacy of the Bimatoprost Implant System Used in Combination With the SpyGlass IOL Compared to Timolol Ophthalmic Solution (Rhine)
SpyGlass Pharma
NCT07218783
Evaluation of the Safety and Efficacy of the Bimatoprost Implant System Used in Combination With the SpyGlass IOL Compared to Timolol Ophthalmic Solution (Rhone)
SpyGlass Pharma
NCT07218796
A Randomized, Double-blind, Parallel-group, Two-arm, Multiple Dose, Multicenter, Bioequivalence Study With Clinical Endpoint in the Treatment of Subjects With Chronic Open-angle Glaucoma or Ocular Hypertension in Both Eyes
Amneal Pharmaceuticals
NCT06267274
Bioequivalence Study With Clinical Endpoint Comparing Bimatoprost Ophthalmic Solution 0.01% and LUMIGAN® in the Treatment of Chronic Open-Angle Glaucoma or Ocular Hypertension in Both Eyes.
Amneal Pharmaceuticals
NCT05401357
24-hour Wear Performance and Safety Study of Smartlens miLens Contact Lens for IOP Monitoring
Smartlens
NCT06689696
AGN-193408 SR in the Treatment of Open-angle Glaucoma or Ocular Hypertension
AbbVie
NCT04499248
Evaluate Efficacy and Safety of PA5108 Ocular Implants in Primary Open Angle Glaucoma or Ocular Hypertension
PolyActiva Pty
NCT06964191
DSLT for Reducing Medication in Glaucoma
The Eye Institute of West Florida
NCT07390890
24-hour Effect of Rocklatan Compared With Latanoprost in Open Angle Glaucoma and Ocular Hypertension Patients
Mayo Clinic
NCT07325240
Nanodropper Use in Primary Open-Angle Glaucoma Patients: A Non-Inferiority Trial
59th Medical Wing
NCT05844384
Biomarkers of Ocular Surface Damage in the Setting of Topical Ocular Hypotensive Medication Use
University of Miami
NCT07217678
Reformulated PG324 Ophthalmic Solution for Intraocular Pressure Reduction
Alcon Research
NCT07082816
Long-term Safety and Efficacy Extension Trial of Bimatoprost SR
AbbVie
NCT03891446
Evaluation of the Bimatoprost Implant System Used in Combination With the SpyGlass Intraocular Lens Compared to Timolol Ophthalmic Solution
SpyGlass Pharma
NCT06120842
Safety Assessment of T4090 Eye Drops in Ocular Hypertensive or Glaucomatous Patients.
Laboratoires Thea
NCT05389267
Evaluation of Netarsudil (AR-13324) Ophthalmic Solution in Patients With Glaucoma and Ocular Hypertension
Aerie Pharmaceuticals
NCT02207621
Double-masked Study of Netarsudil (AR-13324) Ophthalmic Solution in Subjects With Glaucoma or Ocular Hypertension
Aerie Pharmaceuticals
NCT02558374
MRCT Evaluating NCX 470 vs. Latanoprost in Subjects With Open-Angle Glaucoma or Ocular Hypertension
Nicox Ophthalmics
NCT04630808
Efficacy and Safety Assessment of T4032 (Unpreserved Bimatoprost 0.01%) Versus Lumigan® 0.01% in Ocular Hypertensive or Glaucomatous Patients
Laboratoires Thea
NCT05397600
Evaluation of Safety and Efficacy of PDP-716
Sun Pharma Advanced Research Company Limited
NCT03450629
Efficacy and Safety Study of Bimatoprost Sustained-Release (SR) in Participants With Open-angle Glaucoma or Ocular Hypertension
Allergan
NCT02247804
Randomized Study Comparing Two Models of a Travoprost Intraocular Implant to Timolol Maleate Ophthalmic Solution, 0.5%
Glaukos Corporation
NCT03519386
Safety and Efficacy Study of Brimonidine/Timolol Fixed Combination in Patients With Glaucoma or Ocular Hypertension
Allergan
NCT00332436
Safety and Efficacy Study of Bimatoprost/Timolol Fixed Combination in Patients Wtih Glaucoma or Ocular Hypertension
Allergan
NCT00332072
A 12-week, Randomized, Double-masked, Parallel Group Comparison of Evening Dosing With Xalacom in Subjects With Glaucoma
Pfizer's Upjohn has merged with Mylan to form Viatris
NCT00277498
Safety and Efficacy Study of Brimonidine/Timolol Fixed Combination in Patients With Glaucoma or Ocular Hypertension
Allergan
NCT00652106
Comparing the Safety and Efficacy of BOL-303259-X Ophthalmic Solution With Timolol Maleate Ophthalmic Solution in Subjects With Open-Angle Glaucoma or Ocular Hypertension
Bausch & Lomb Incorporated
NCT01749930
Efficacy, Tolerability and Safety of RKI983 (0.05% & 0.10%) vs Xalatan in Patients With POAG or Ocular Hypertension
Novartis Pharmaceuticals
NCT00846989
Bimatoprost 0.03% Versus Travoprost 0.004% in Patients Currently on Latanoprost 0.005%
Allergan
NCT00440011
18 Month Prospective Efficacy and Safety Study of Bimatoprost Intracameral Implant (DURYSTA)
Allergan
NCT04647214
Study of Safety and Efficacy of H-1337 in Subjects With Primary Open Angle Glaucoma or Ocular Hypertension
D. Western Therapeutics Institute
NCT05913232
Study to Assess the Efficacy, Safety and Tolerability of AKB-9778 Ophthalmic Solution as and Adjunct to Latanoprost in Patients With Ocular Hypertension or Open Angle Glaucoma
EyePoint Pharmaceuticals
NCT04405245
Dose-Finding Study Comparing the Safety and Efficacy of Latanoprost to a Novel Treatment for Glaucoma
Bausch & Lomb Incorporated
NCT00441883
Pigment Dispersion Syndrome With and Without Glaucoma
National Eye Institute (NEI)
NCT00001152
Ocular Surface Tolerability Study of Prostaglandin Analogues in Patients With Open-Angle Glaucoma or Ocular Hypertension
Allergan
NCT01253902
Safety and Efficacy of AGN-210961 Ophthalmic Solution Compared With Bimatoprost Ophthalmic Solution in Patients With Glaucoma or Ocular Hypertension
Allergan
NCT01110499
Evaluation of Safety of SPARC0913 in Open Angle Glaucoma or Ocular Hypertension
Sun Pharma Advanced Research Company Limited
NCT00945958
A Dose-Escalation Study Designed to Evaluate the Tolerability, Safety, Pharmacokinetics (PK), and Efficacy of Chronic Topical Ocular Application of INO-8875 in Adults With Ocular Hypertension or Primary Open-Angle Glaucoma
Inotek Pharmaceuticals Corporation
NCT01123785
A 28 Day Study of ONO-9054 Ophthalmic Solution in Subjects With Ocular Hypertension (OHT) or Open-angle Glaucoma (OAG)
Ono Pharmaceutical Co.
NCT02083289
A Safety and Efficacy Study of Fixed-Combination Bimatoprost and Brimonidine in Chronic Glaucoma or Ocular Hypertension
Allergan
NCT01863953
Study to Evaluate QLS-101 Compared to Timolol Maleate Eye Drops in Subjects With High Eye Pressure (Glaucoma or Ocular Hypertension).
Qlaris Bio
NCT04830397
Multiple Dose-escalation Study of AMA0076 in Patients With Ocular Hypertension or Primary Open-angle Glaucoma
Amakem
NCT01693315
A Phase IIIb Study of DuoTrav to Treat Glaucoma or Ocular Hypertension
Alcon Research
NCT00465803
Safety and IOP-Lowering Effects of WB007
Bausch & Lomb Incorporated
NCT04149899
Study of SHP639 Eye Drops in Adults With High Eye Pressure or Primary Open-angle Glaucoma
Shire
NCT03131167
Travoprost Five Day Posology Study
Alcon Research
NCT01114893
Intraocular Pressure During Robotic Assisted Laparoscopic Procedures Utilizing Steep Trendelenburg Positioning
United States Naval Medical Center, San Diego
NCT01261871
Safety and Efficacy of a Glaucoma Drug Delivery System
Vistakon Pharmaceuticals
NCT00824720
Comparison of Combigan Two Times Daily (BID) Versus Simbrinza Three Times Daily (TID)
Cornerstone Health Care, PA
NCT02167035
Diurnal and Nocturnal Effect of Travatan With SofZia Preservative on Intraocular Pressure and Ocular Perfusion Pressure
University of Colorado, Denver
NCT01779778
Effects of a Single OMT on Intraocular Pressure (IOP) in Ocular Hypertenive or Glaucoma Suspect Subjects
University of Wisconsin, Madison
NCT01864642
The Effect of a Scleral Lens on the Anterior Chamber Depth and Minimum Rim Width
University of Houston
NCT03926975
Retinal Effects of Balance Goggles System in Glaucoma Balance Goggles System (BGS) in Patients With Glaucoma
Stanford University
NCT04035239
Study of ST266 Given by Intranasal Delivery in Glaucoma Suspect Subjects
Noveome Biotherapeutics, formerly Stemnion
NCT03901781
A 6-Week Safety and Efficacy Study of Travatan Compared to Xalcom in Subjects With Open-Angle Glaucoma(OAG) or Ocular Hypertension(OHT)
Alcon Research
NCT00051155
Phase 3 Study to Evaluate IOP Lowering Therapy in Open Angle Glaucoma and Ocular Hypertension C-01-70
Alcon Research
NCT00047541
Phase Distribution
| Phase | Trial count |
|---|---|
| Early Phase 1 | 10 |
| Phase 2 | 11 |
| Phase 3 | 21 |
| Phase 4 | 5 |
Top Sponsors
Source: ClinicalTrials.gov, National Library of Medicine. Data is informational only.
Reading the Ocular Hypertension Trial Landscape
ClinicalTrials.gov lists 57 US studies indexed under Ocular Hypertension, and 12 of those are currently open to recruitment — roughly 21% of the total volume on the registry. That ratio is a useful proxy for activity level: a high share of recruiting studies often signals that research interest is current and that new enrollment opportunities are appearing, while a low share typically means the field is dominated by completed or follow-up work where most participant spots have already been filled. These counts reflect the public registry only and include studies at every stage of design, so they should be read as an index of research attention rather than as a measure of treatment availability.
The phase distribution for Ocular Hypertension shows 26 late-stage studies (Phase 3 and Phase 4 combined) alongside 21 earlier-phase entries (Phase 1 through Phase 2). Phase 1 and Phase 2 studies focus on early safety signals, dosing, and preliminary effect, while Phase 3 studies are typically the larger efficacy and safety trials submitted toward regulatory review, and Phase 4 studies follow approved interventions in real-world use. A condition weighted toward later phases often reflects a mature research pipeline with several interventions already close to or past approval, whereas a heavier early-phase tilt suggests the field is still exploring new mechanisms and candidate approaches.
Top sponsor activity for Ocular Hypertension is led by Allergan with 9 indexed trials, alongside 9 other organizations in the top contributor list. The list on this page surfaces up to 57 of the most relevant recent and active entries, ordered with recruiting studies first so practical options are visible. All figures are derived from the public ClinicalTrials.gov dataset maintained by the National Library of Medicine and are reproduced here for reference. Inclusion of a trial, sponsor, or intervention on this page is neither an endorsement nor a recommendation — eligibility, protocol changes, and site-level status can shift frequently, so always verify current details on ClinicalTrials.gov and consult a qualified healthcare provider before acting on anything you see here.
Frequently Asked Questions
How many clinical trials are there for Ocular Hypertension?
PlainTrial tracks 57 US clinical trials for Ocular Hypertension, of which 12 are currently recruiting participants. Data sourced from ClinicalTrials.gov.
How do I find a recruiting trial for Ocular Hypertension?
Use the trial list above filtered by "Recruiting" status, or visit our trial finder at /recruiting to search by condition and state. Always discuss trial participation with your healthcare provider before enrolling.
Is this data current?
Data is sourced from ClinicalTrials.gov and reflects our most recent data pull. Trial status may have changed since then. Always verify current information at ClinicalTrials.gov before making decisions about participation.
Related
Disclaimer: This information is provided for informational purposes only and does not constitute professional advice. Data is sourced from ClinicalTrials.gov (National Library of Medicine). Consult a qualified professional before making decisions based on this data.
Read our methodology — how this data is sourced, computed, and verified.
Source: ClinicalTrials.gov (NIH/NLM) ClinicalTrials.gov AACT registry · 2024 Trial counts and statuses sourced from ClinicalTrials.gov. Sponsor counts include both industry and federal/academic sponsors.